129 related articles for article (PubMed ID: 26527886)
1. SOX2 expression is associated with FGFR fusion genes and predicts favorable outcome in lung squamous cell carcinomas.
Zheng S; Pan Y; Wang R; Li Y; Cheng C; Shen X; Li B; Zheng D; Sun Y; Chen H
Onco Targets Ther; 2015; 8():3009-16. PubMed ID: 26527886
[TBL] [Abstract][Full Text] [Related]
2. Morphologic and clinicopathologic features of lung squamous cell carcinomas expressing Sox2.
Brcic L; Sherer CK; Shuai Y; Hornick JL; Chirieac LR; Dacic S
Am J Clin Pathol; 2012 Nov; 138(5):712-8. PubMed ID: 23086772
[TBL] [Abstract][Full Text] [Related]
3. FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer.
Flockerzi FA; Roggia C; Langer F; Holleczek B; Bohle RM
Virchows Arch; 2018 May; 472(5):759-769. PubMed ID: 29270870
[TBL] [Abstract][Full Text] [Related]
4. Overexpression of SOX2 Is Associated with Better Overall Survival in Squamous Cell Lung Cancer Patients Treated with Adjuvant Radiotherapy.
Yoon HI; Park KH; Lee EJ; Keum KC; Lee CG; Kim CH; Kim YB
Cancer Res Treat; 2016 Apr; 48(2):473-82. PubMed ID: 26323639
[TBL] [Abstract][Full Text] [Related]
5. Sex determining region Y-box 2 (SOX2) amplification is an independent indicator of disease recurrence in sinonasal cancer.
Schröck A; Göke F; Wagner P; Bode M; Franzen A; Braun M; Huss S; Agaimy A; Ihrler S; Menon R; Kirsten R; Kristiansen G; Bootz F; Lengerke C; Perner S
PLoS One; 2013; 8(3):e59201. PubMed ID: 23544055
[TBL] [Abstract][Full Text] [Related]
6. Detection of MET and SOX2 amplification by quantitative real-time PCR in non-small cell lung carcinoma.
Cai YR; Zhang HQ; Zhang ZD; Mu J; Li ZH
Oncol Lett; 2011 Mar; 2(2):257-264. PubMed ID: 22866074
[TBL] [Abstract][Full Text] [Related]
7. Co-active receptor tyrosine kinases mitigate the effect of FGFR inhibitors in FGFR1-amplified lung cancers with low FGFR1 protein expression.
Kotani H; Ebi H; Kitai H; Nanjo S; Kita K; Huynh TG; Ooi A; Faber AC; Mino-Kenudson M; Yano S
Oncogene; 2016 Jul; 35(27):3587-97. PubMed ID: 26549034
[TBL] [Abstract][Full Text] [Related]
8. SOX2 amplification is a common event in squamous cell carcinomas of different organ sites.
Maier S; Wilbertz T; Braun M; Scheble V; Reischl M; Mikut R; Menon R; Nikolov P; Petersen K; Beschorner C; Moch H; Kakies C; Protzel C; Bauer J; Soltermann A; Fend F; Staebler A; Lengerke C; Perner S
Hum Pathol; 2011 Aug; 42(8):1078-88. PubMed ID: 21334718
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Inoue Y; Matsuura S; Kurabe N; Kahyo T; Mori H; Kawase A; Karayama M; Inui N; Funai K; Shinmura K; Suda T; Sugimura H
J Thorac Oncol; 2015 Nov; 10(11):1590-600. PubMed ID: 26536195
[TBL] [Abstract][Full Text] [Related]
10. SOX2 Gene Amplification and Overexpression is Linked to HPV-positive Vulvar Carcinomas.
Gut A; Moch H; Choschzick M
Int J Gynecol Pathol; 2018 Jan; 37(1):68-73. PubMed ID: 28700423
[TBL] [Abstract][Full Text] [Related]
11. FGFR1/3 tyrosine kinase fusions define a unique molecular subtype of non-small cell lung cancer.
Wang R; Wang L; Li Y; Hu H; Shen L; Shen X; Pan Y; Ye T; Zhang Y; Luo X; Zhang Y; Pan B; Li B; Li H; Zhang J; Pao W; Ji H; Sun Y; Chen H
Clin Cancer Res; 2014 Aug; 20(15):4107-14. PubMed ID: 24850843
[TBL] [Abstract][Full Text] [Related]
12.
Wang X; Ge X; Wang H; Huang J; Song Q; Xu C; Jiang Z; Su J; Wang H; Tan L; Jiang D; Hou Y
Ann Transl Med; 2021 Feb; 9(4):321. PubMed ID: 33708948
[TBL] [Abstract][Full Text] [Related]
13. Increased Sox2 copy number in lung squamous cell carcinomas.
Sasaki H; Yokota K; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Exp Ther Med; 2012 Jan; 3(1):44-48. PubMed ID: 22969842
[TBL] [Abstract][Full Text] [Related]
14. High SOX2 levels predict better outcome in non-small cell lung carcinomas.
Velcheti V; Schalper K; Yao X; Cheng H; Kocoglu M; Dhodapkar K; Deng Y; Gettinger S; Rimm DL
PLoS One; 2013; 8(4):e61427. PubMed ID: 23620753
[TBL] [Abstract][Full Text] [Related]
15. A subtype of oral, laryngeal, esophageal, and lung, squamous cell carcinoma with high levels of TrkB-T1 neurotrophin receptor mRNA.
Zhou Y; Sinha S; Schwartz JL; Adami GR
BMC Cancer; 2019 Jun; 19(1):607. PubMed ID: 31221127
[TBL] [Abstract][Full Text] [Related]
16. Association of SOX2 and Nestin DNA amplification and protein expression with clinical features and overall survival in non-small cell lung cancer: A systematic review and meta-analysis.
Li Q; Liu F; Zhang Y; Fu L; Wang C; Chen X; Guan S; Meng X
Oncotarget; 2016 Jun; 7(23):34520-31. PubMed ID: 27150062
[TBL] [Abstract][Full Text] [Related]
17. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study.
Lee HJ; Xu X; Choe G; Chung DH; Seo JW; Lee JH; Lee CT; Jheon S; Sung SW; Chung JH
Lung Cancer; 2010 Jun; 68(3):375-82. PubMed ID: 19712993
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of CHD1L is positively associated with metastasis of lung adenocarcinoma and predicts patients poor survival.
He LR; Ma NF; Chen JW; Li BK; Guan XY; Liu MZ; Xie D
Oncotarget; 2015 Oct; 6(31):31181-90. PubMed ID: 26360781
[TBL] [Abstract][Full Text] [Related]
19. SOX2 expression in hypopharyngeal, laryngeal, and sinonasal squamous cell carcinoma.
González-Márquez R; Llorente JL; Rodrigo JP; García-Pedrero JM; Álvarez-Marcos C; Suárez C; Hermsen MA
Hum Pathol; 2014 Apr; 45(4):851-7. PubMed ID: 24656096
[TBL] [Abstract][Full Text] [Related]
20. Genetic alteration profiling of patients with resected squamous cell lung carcinomas.
Tao D; Han X; Zhang N; Lin D; Wu D; Zhu X; Song W; Shi Y
Oncotarget; 2016 Jun; 7(24):36590-36601. PubMed ID: 27145277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
